AstraZeneca To Invest $2.5B In China Research Hub
By Jade Martinez-Pogue
Pharmaceutical giant AstraZeneca on Friday announced plans to invest $2.5 billion in Beijing over the next five years to establish a new global strategic research and development center, inking agreements with three biotechs to help develop new treatments and advance life sciences in China.